• DexTech Medical completed the clinical study report for its Phase I/IIa OsteoDex multiple myeloma trial, confirming previously disclosed preliminary results.
• All patients with progressive, treatment-resistant disease achieved stable disease during treatment; most maintained stability following treatment without additional anticancer therapy.
• No serious OsteoDex-related adverse events were recorded, supporting its safety profile and potential use in combination therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexTech Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 20261027:BIT:0544:0) on October 27, 2026, and is solely responsible for the information contained therein.